The role and efficacy of filgotinib

Filgotinib (Filgotinib) is an oral, priority Janus kinase (JAK)-1 inhibitor. Preferential inhibition of JAK1 regulates a subset of pro-inflammatory cytokines in the JAK signaling and transcriptional activation pathways that are distinct from those inhibited by JAK2 or JAK3. After oral administration, filgotinib is extensively and rapidly absorbed and metabolized by carboxylesterase isomer 2 to form its primary active metabolite GS-829845. The primary metabolite has similar JAK1 selectivity characteristics but reduced activity (10-fold) and increased systemic exposure (approximately 16- to 20-fold) compared to the parent compound.

Over the dose range of 50-200 mg once daily systemic exposure to filgotinib and its major metabolite will increase proportionally to the dose. Food does not affect the pharmacokinetics of filgotinib. Consistent with the terminal elimination half-life, it was 4.9-10.7 hours for filgotinib and 19.6-27.3 hours for the primary metabolite, with its metabolites reaching plasma steady state on days 2 and 4. Figotinib is eliminated primarily as metabolites (>80%) in the urine. Filgotinib has a low drug interaction potential and has no clinically significant interactions with co-medications commonly used in patients with inflammatory diseases. In Europe, the United Kingdom, and Japan, filgotinib is approved for the treatment of rheumatoid arthritis and ulcerative colitis.

The original drug filgotinib has not yet been launched in China, and therefore is not included in medical insurance. The Bangladeshi version of the filgotinitine generic drug currently on the market overseas, specifications100mg*30 tablets may cost more than 500 yuan per box (the price may fluctuate due to exchange rates), and its drug ingredients are basically the same as those of the original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.